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Abstract
Purpose of Review—Electronic cigarette (e-cigarette) use is rapidly increasing, with many 
users reporting trying e-cigarettes as a method to quit combustible cigarettes. This review 
highlights recently published studies assessing the use of e-cigarettes as a tool for cessation of 
combustible cigarettes.
Recent Findings—When evaluating data from four randomized controlled trials and multiple 
cohort studies, differential association between e-cigarette use and cessation rates was seen. 
Cessation rates are highest in UK cohort studies and in studies using a multi-faceted approach, 
such as with the addition of varenicline. The largest evidence base is derived from observational 
cohort studies. Overall, the current evidence remains too small for conclusive results regarding 
efficacy of e-cigarettes for combustible cessation. There does appear to be a consistent reduction in 
daily combustible cigarette use in regular e-cigarette users.
Summary—Currently, there are conflicting data which can be used to support or dismiss e-
cigarettes as a tool for smoking cessation. As larger population-based studies become available, 
the potential harms and benefits of e-cigarette will become clearer. In the short term, shared 
decision making with combustible cigarette users will be imperative when considering e-cigarettes 
as a smoking cessation tool.
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Introduction
E-cigarettes, also known as electronic nicotine delivery systems, are battery operated devices 
which deliver nicotine by heating and aerosolizing a nicotine containing solution. E-
cigarettes have three key components: a power source, an electronic heating element, and 
liquid-containing nicotine cartridge. The liquid in the cartridge contains varying 
concentrations of nicotine and flavorings in a stabilizing liquid vehicle. When the user 
activates the heating element, a nicotine-containing liquid aerosolizes and is subsequently 
inhaled (1, 2). E-cigarettes have been marketed as an alternative to traditional combustible 
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cigarettes. E-cigarettes became available in the US in 2007 with increasing awareness and 
popularity, leading to approximately 15% of US adults in 2014 reporting trying an e-
cigarette (1, 3, 4). Current smokers and those reporting recent cessation comprise the largest 
fraction of e-cigarette users, with approximately 50% of these groups in the US, and 40% in 
Great Britain reporting use (3–5). Among both current and former smokers the most 
commonly cited reasons for the use of e-cigarettes were perceived health benefits when 
compared to combustible cigarettes, followed by assistance with smoking cessation (5). 
These epidemiological data highlight that e-cigarette users are integrating these devices as a 
smoking cessation tool. What remains unclear is whether the current state of scientific 
evidence supports this social phenomenon. The purpose of this review is to summarize the 
recent literature regarding the efficacy of e-cigarettes to impact smoking cessation. With 
these data, clinicians, policy makers and e-cigarette users can better understand the potential 
role of e-cigarettes in smoking cessation.
Acute Toxicity of E-Cigarettes
Any consideration of e-cigarettes as a cessation tool must incorporate a discussion of the 
known harms of these devices. Heterogeneity in e-cigarette device design leads to 
substantial heterogeneity in vapor constituents (2, 6). Vapor analysis of 12 brands of e-
cigarettes revealed the presence of many toxic chemicals including carbonyl compounds, 
volatile organic compounds, carcinogenic nitrosamines and heavy metals (7). These toxins 
were present at concentrations 9–450 times lower than that seen in cigarette smoke. Recent 
studies have reported that super-heating of glycol derivatives, achievable with newer higher 
voltage “tank” devices, increases the generation of potentially carcinogenic carbonyl 
compounds (8). While the preponderance of data support that e-cigarettes generate toxic 
compounds at levels less than combustible cigarettes, it is unclear if these levels are below a 
threshold for harm. Moreover, given the relative infancy of e-cigarette use, it will likely be 
decades before long-term harm data are available. These uncertainties have been used as 
evidence by both proponents and opponents of e-cigarettes to support their claims of benefits 
or harms.
Randomized-Controlled Trials of E-Cigarettes for Cessation
Currently, there are limited clinical trials to assist health care providers when counselling 
patients on the role of e-cigarettes as a cessation tool. Four randomized controlled trials 
(RCTs) have directly studied e-cigarettes usage for smoking cessation (9–12) (Table 1). The 
largest study was conducted by Bullen and colleagues in New Zealand between 2011 – 
2013(11). This study recruited 657 smokers interested in quitting to receive low intensity 
behavioral support along with either 16 mg nicotine e-cigarette, 21 mg nicotine patch or 
placebo e-cigarette for 6 months. Biochemically verified abstinence at 6 months was the 
primary outcome. At 6-months, there was no difference in the biochemically-confirmed 
smoking abstinence: 7.3% nicotine e-cigarette, 5.8% nicotine patch, 4.1% placebo e-
cigarette (nicotine versus placebo e-cigarette p=0.44; nicotine e-cigarette versus patch 
p=0.46). Notably, 57% of patients in the nicotine e-cigarette decreased their daily number of 
cigarettes smoked by at least half compared with 41% of participants randomized to nicotine 
patch (p=0.0002).
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The 2013 “Efficiency and Safety of an Electronic Cigarette as Tobacco Cigarettes 
Substitute” study by Caponnetto and colleagues randomized 300 Italian smokers not 
interested in quitting to either 1) 7.2 mg e-cigarette for 12 weeks, 2) 7.2 mg e-cigarette for 6 
weeks then 5.4 mg e-cigarette for 6 weeks or 3) 0 mg e-cigarette for 12 weeks.(10) After 12 
weeks, participants were advised to continue using their e-cigarette if they wished, but no 
additional cartridges were provided by investigators. Participants were subsequently 
followed for an additional 40 weeks. At the end of the study period of 52 weeks, overall 
cessation rates were 11% in the 7.2 mg group, 13% in the 5.4 mg group and 4% in the 
placebo group (p=0.24 for overall difference). At 52 weeks, 9–12% of smokers in all three 
groups had reduced their baseline cigarette usage by half with no significant differences 
between groups.
A 2014 RCT by Adriaens and colleagues randomized 48 smokers who were not wanting to 
quit to either a control group with no intervention, or to one of two different brands of 
refillable second generation e-cigarettes with 18 mg nicotine containing solution (12). The 
primary aim of the study was to evaluate acute cravings over a span of 8 weeks in relation to 
successful sustained smoking reduction. An e-cigarette group was permitted to use the 
device for eight weeks, while the control group was asked to avoid e-cigarettes. All groups 
were followed for six months after the eight-week study. At six months, cessation rates were 
19% for the e-cig group and 25% for the control group (p-value for difference not provided). 
A total of 60% fewer cigarettes were smoked per day across all groups, however only 23% 
participants had a >50% reduction in number of cigarettes smoked.
The most recently published RCT by Tseng and colleagues enrolled 99 New York residents 
(9). After a brief counseling session, participants were asked to reduce cigarette 
consumption by 50%, and were then randomized in a double-blinded fashion to either 
nicotine e-cigarette or placebo e-cigarette, and then followed for three weeks. They were not 
offered other nicotine replacement therapy, and were excluded if already on nicotine 
replacement therapy. Formal assessment of cessation was not a pre-specified outcome of this 
study, but no participants reported complete cessation at follow-up. After three weeks there 
was a significant reduction in cigarettes per day smoked in both groups (p<0.001). The odds 
of achieving at least 50% reduction in users of nicotine e-cigarettes was 3.2-fold greater than 
placebo e-cigarettes (p=0.034).
So how are we to incorporate these data into an assessment of the value of e-cigarettes as a 
cessation tool? Taken individually or in total, the available RCTs demonstrate that e-
cigarettes are no better and no worse than placebo or nicotine replacement as a tool for 
smoking cessation. However, all RCTs are limited by variable outcome assessments, 
inadequate sample size, and diverse study populations of smokers. The most recent 
Cochrane review published in September 2016 found that data pooled from the studies by 
Bullen and Caponnetto support an effect of nicotine e-cigarettes on cessation when 
compared to placebo e-cigarettes, but grades the confidence in these conclusion as low given 
the few trials, low event rates and wide confidence intervals (13). The study by Bullen and 
colleagues is the only RCT to compare e-cigarettes to standard nicotine replacement therapy, 
which is the most relevant comparator for clinicians. Unfortunately, the fixed dose nicotine 
replacement used in that study has been shown to be less effective than dual replacement 
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approached (i.e., patch and gum) (14, 15). Moreover, the trial design placed the nicotine 
replacement group at a disadvantage compared to the e-cigarette group, as the nicotine 
replacement group was given vouchers for patches while the e-cigarette group was directly 
provided e-cigarettes. It is tempting to speculate that e-cigarettes may have been less 
effective than nicotine replacement if these study weaknesses were not present. Despite this, 
Bullen and colleagues should be commended for embarking on a rigorous and relevant 
comparator design. Study designs comparing established cessation practices should be a 
focus of future randomized control trials as to obtain the most clinically relevant data.
Cohort Studies of E-Cigarettes for Cessation
Given that conclusive data from RCTs is unlikely to be available in the near future, 
clinicians may look to data from observational studies to derive conclusions about the role of 
e-cigarettes for cessation. While these data do not meet the “gold standard” of scientific 
proof attributed to RCTs, they are informative in that these study designs are more reflective 
of the real world setting. A recent non-randomized trial from London included offering e-
cigarettes to all smokers seeking help from the UK’s Stop Smoking Services (16). E-
cigarettes were offered in addition to the standard treatment of behavioral support and 
medications. Of 100 smokers, 69 opted in for e-cigarette use. In addition to e-cigarette use, 
20 participants also opted to use varenicline while 23 opted to use nicotine replacement 
therapy. Of those who trialed e-cigarettes, 68% reported cessation in the e-cigarette group at 
four-week follow-up compared with 45% of smokers not using e-cigarettes (p=0.06). There 
was a significantly higher cessation in smokers who used varenicline plus e-cigarette 
compared to those using e-cigarette alone (85% vs. 54%; p=0.03). The higher rates of 
cessation using a multi-faceted approach suggests that combination therapy which 
incorporates e-cigarettes with non-nicotine pharmacotherapy warrants additional 
exploration.
Two large longitudinal cohort studies have examined the association of intensive (i.e., daily) 
use of e-cigarettes with cessation of combustible cigarettes (17, 18). Brose and colleagues 
examined surveyed 4064 adult smokers in the UK at baseline and one-year later with a 
retention rate of 43% at follow up. The authors found an association between e-cigarette use 
and increased quit attempts (OR 2.11; 95% CI 1.24–3.58; p=0.006), but no association 
between e-cigarette use and cessation (OR 0.62; 95% CI 0.27–1.37; p=0.24) (17). Biener 
and colleagues surveyed 1374 US smokers at baseline and 2–3 years later (51% retention 
rate) (18). Self-reported one-month cessation rates were 12% for e-cigarette non-users, 9% 
for non-daily e-cigarette users and 20% for daily e-cigarette users (overall p=0.50). In 
adjusted analyses, compared to non-users, regular e-cigarette users were six times more 
likely to quit smoking (OR 6.07; 95% CI 1.11–33.2). No association was observed between 
non-daily e-cigarette use and cessation. These results are consistent with a previously 
published cohort study of 1549 US smokers which observed that e-cigarette use as baseline 
was not associated with cessation one-year later (OR 0.71; 95% CI 0.35–1.46; p=0.35) (19).
Two UK cohort studies have shown that e-cigarettes are associated with increased cessation 
of combustible cigarettes (20, 21). Brown and colleagues enrolled 5863 participants in a 
retrospective cross-sectional study in England evaluating adults who had attempted to quit 
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smoking within the past 12 months (20). Participants were asked about their number of quit 
attempts, use of nicotine replacement therapy, use of e-cigarettes and smoking urges. Non-
smoking was reported among 20% of e-cigarette users, 10% of nicotine replacement users 
and 15% of those using no aid. Use of e-cigarettes increased the odds of self-reported 
abstinence compared with nicotine replacement therapy (OR 2.23; 95% CI 1.70–2.93) or no 
cessation aid (OR 1.38; 95% CI 1.08–1.76). The association between e-cigarette use and 
self-reported abstinence persisted after adjusting for potential confounders including age, 
sex, social grade, nicotine dependence and prior quit attempts. Extrapolated data from this 
study estimates that 19,000–22,000 long term quitters were generated with the assistance 
from e-cigarettes (22). Recently Beard and colleagues reported findings from 1200 smokers 
in the UK Smoking Toolkit Study, a cross-sectional population based survey (21). In 2016, 
21% of the cohort reported using e-cigarettes and 18.6% reported successful quit attempts. 
Self-reported success rates of quit attempts increased by 0.98% for every 1% increase in 
prevalence of e-cigarette use (95% CI 0.64–1.32%; p<0.001). E-cigarette use during a quit 
attempt was associated with 0.58% increase in successful quit attempts for every 1% 
increase in e-cigarette use (95% CI 0.38–0.78%; p<0.001).
The recent cohort studies have yielded conflicting results, with some demonstrating no 
differential impact on smoking cessation rates, while others have demonstrated efficacy. The 
cohort studies suffer the limitations inherent in cohort studies, namely observational design 
without standardized interventions, self-reported outcomes, and low retention rates.
Conclusions
When assessing the preponderance of available data regarding e-cigarettes and smoking 
cessation, it is evident that these devices are not clearly superior to approved nicotine 
replacement therapy or “usual care.” Importantly however, the current data also show that 
these devices are not clearly inferior to approved nicotine replacement therapy or “usual 
care.” This counterpoint highlights the need for equipoise when evaluating e-cigarettes as a 
potential cessation tool. Pooled data from the available studies demonstrates no increased 
serious adverse events related to e-cigarettes for up to two years of follow-up (13). Longer 
term safety is not known. Although inconclusive, the currently available data informs several 
realities of e-cigarettes in the cessation landscape:
• E-cigarette use is rapidly increasing and most prevalent among current smokers.
• E-cigarettes are no more or less effective than nicotine replacement therapy for 
cessation.
• Incorporation of e-cigarettes with varenicline and other non-nicotine 
pharmacotherapies warrants further investigation.
• Reduction of combustible cigarette use is seen with regular e-cigarette users.
• When compared to combustible cigarettes, e-cigarettes have less acute toxic 
effects.
• Long term effects of e-cigarettes remain unknown.
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Interpretations of the currently available date regarding e-cigarettes for cessation differ 
widely by medical and regulatory bodies (23–27). The Public Health England (PHE) has 
issued a statement encouraging the use of e-cigarettes for smokers who could not, or would 
not, quit smoking tobacco (28, 29). PHE supported the reduced harm approach by providing 
an estimate of e-cigarettes being 95% safer than cigarette smoking (28). Additionally, Action 
on Smoking Health, UK’s public health charity which focuses on eliminating the harm 
caused by tobacco, has denounced the notion that e-cigarettes act as a gateway drug to 
cigarette use (29). This is in contrast to the recommendations from US regulatory bodies 
including the US Preventive Services Task Force and Centers for Disease Control and 
Prevention (CDC), recommending against the use of e-cigarettes for cessation given 
insufficient data (24, 30). These discrepant messages, derived from assessment of the same 
body of data, only contribute to the confusion for clinicians, smokers, and e-cigarette users. 
It is possible that these differing regional guidelines will provide a natural experiment at the 
global level regarding the impact of e-cigarettes on cessation, as is currently being observed 
with the recent UK publications (20, 21).
In summary, regarding e-cigarettes for smoking cessation, are we there yet? The simple 
answer is no. However, researchers, policy makers and e-cigarette users must re-assess what 
level of evidence will get us there. Definitive RCTs will continue to be difficult to design, 
will require replication and may never give a conclusive answer to individuals without 
equipoise on this issue. Cohort studies, while convenient, will also lack definitive findings. 
Long term studies, required to understand harms of e-cigarettes, will not be forthcoming in 
the near future. Meanwhile, e-cigarette use by tobacco smokers as a cessation tool is likely 
to continue to increase. As shared decision making is becoming the new standard of care for 
medical treatments, it is imperative to engage e-cigarette users in the scientific process. 
Researchers should engage e-cigarette users to ensure appropriate study designs which 
replicate real-world us, perhaps abandoning rigid RCTs for rigorous population-level cohort 
studies. Clinicians’ discussions with users should include clear explanations of the 
certainties and uncertainties surrounding e-cigarettes. It is our practice to recommend 
approved cessation therapies (e.g., nicotine replacement therapy, varenicline) for individuals 
inquiring about e-cigarettes. Only if patients have failed these therapies, or are unwilling to 
try them, do we then discuss e-cigarettes as a bridge to complete cessation. Policy makers 
should embrace equipoise when interpreting the potential benefits and harms of e-cigarettes. 
As the scientific knowledge about e-cigarettes and cessation accumulates, all stakeholders 
should balance the uncertainty of unknown harms of e-cigarettes with the known harms of 
continued combustible cigarette use.
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KEY POINTS
• Randomized controlled trials have not demonstrated that e-cigarettes are an 
effective cessation tool
• Cohort studies have yielded conflicting results, with some demonstrating that 
e-cigarette use is associated with enhanced cessation
• Reduction in daily combustible cigarette use is seen with e-cigarette use, but 
does not relate to increased cessation
• Researchers, users and policy makers should maintain equipoise when 
assessing the efficacy of e-cigarettes for cessation given conflicting data
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